Skip to content

Lonza | Invests CHF 650 million in Visp

Share this article

Significant investments to expand its mammalian drug substance manufacturing facilities in Visp

The Lonza‘s expansion in Visp (Valais, Switzerland) will see the development of a new large-scale mammalian drug substance manufacturing facility to expand capacity with six 20,000L bioreactors to meet increasing market demand in biologics. The new facility will have an area of approximately 27,500 m2.

The investment will increase large-scale biologics manufacturing capacity to meet customer demand in the contract manufacturing space. The state-of-the-art, high throughput facility includes perfusion capabilities and is designed to support high titer processes and accommodate the next generation of mammalian biologics.

Designed to optimise energy efficiency and water use, the facility is expected to be completed in 2024 and will require an investment of approximately CHF 650 million. The expansion will complement the existing large-scale global network at Lonza sites in Tuas (SG), Portsmouth (US) and Porriño (ES).


Press Release